Frazier Life Sciences Management, L.P. Verona Pharma PLC Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q2 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Verona Pharma PLC stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 3,383,950 shares of VRNA stock, worth $356 Million. This represents 16.88% of its overall portfolio holdings.
Number of Shares
3,383,950
Previous 3,457,850
2.14%
Holding current value
$356 Million
Previous $220 Million
45.78%
% of portfolio
16.88%
Previous 13.82%
Shares
8 transactions
Others Institutions Holding VRNA
# of Institutions
322Shares Held
76.7MCall Options Held
977KPut Options Held
3.12M-
Janus Henderson Group PLC London, X06.13MShares$645 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$579 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$434 Million16.48% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$321 Million4.43% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.72MShares$286 Million4.88% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.41B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...